Public sector replacement of privately funded pharmaceutical R&D: cost and efficiency considerations
The bulk of investment in R&D is underwritten by the private sector. Political discourse portraying the NIH as the central force in bringing a new drug to market may underappreciate the pivotal role of private at-risk capital. Replacing such investment while maintaining the current innovation output in terms of approved therapies would necessitate substantial increases in taxpayer financing.
Authors
- Dave Nellesen
- Susan Martin (ORCID: https://orcid.org/0000-0002-9594-5036)
- Urvi Desai (ORCID: https://orcid.org/0000-0001-5196-7201)
- Henry G. Grabowski
- David Proudman (ORCID: https://orcid.org/0000-0002-2295-3473)
- Aparna Gomes (ORCID: https://orcid.org/0000-0003-4498-8201)
- Maks Khomenko
- U. Neumann (ORCID: https://orcid.org/0000-0001-8525-9334)
Institutions
- Johnson & Johnson (United States) (US)
- Duke University (US)
- Analysis Group (United States) (US)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2024-10-03
- DOI
- https://doi.org/10.1080/13696998.2024.2405407
- Citations
- 2
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 2.26